Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Hazard Ratio01:12

Hazard Ratio

114
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
114
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Risk Stratification Of Patients With Recurrence After Primary Treatment For Prostate Cancer: A Systematic Review

Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review

Adam B Weiner1, Preeti Kakani2, Andrew J Armstrong3

  • 1Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California Los Angeles, Los Angeles, CA, USA.

European Urology
|May 23, 2024

Related Experiment Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

252

View abstract on PubMed

Summary
This summary is machine-generated.

Identifying prognostic factors for biochemical recurrence (BCR) in prostate cancer (PCa) is crucial for personalized salvage treatment. Key predictors include PSA doubling time, recurrence timing, and specific molecular markers post-prostatectomy or radiotherapy.

Area of Science:

  • Oncology
  • Urology
Keywords:
AbirateroneAndrogen deprivation therapyApalutamideBiochemical recurrence

Related Experiment Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.7K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

252
  • Medical Informatics

    • Background:

    • Biochemical recurrence (BCR) after prostate cancer (PCa) treatment is heterogeneous.
    • Risk stratification is needed to guide salvage therapy decisions.
    • Prognostic factors for adverse outcomes post-recurrence require identification.

    Purpose of the Study:

    • To identify prognostic risk factors for adverse oncologic outcomes in PCa patients experiencing BCR.
    • To stratify risk prior to initiating salvage treatment after radical prostatectomy or radiotherapy.

    Main Methods:

    • Systematic review of prospective studies (2000-2023) from EMBASE, MEDLINE, and ClinicalTrials.gov.
    • Analysis of factors associated with oncologic outcomes in patients with BCR.
    • Adherence to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

    Main Results:

    • Post-prostatectomy BCR: Higher pathologic T stage/grade, negative margins, shorter PSA doubling time (PSADT), higher PSA, shorter recurrence time, 22-gene signature, and imaging recurrence location predict adverse outcomes.
    • Post-radiotherapy BCR: Shorter time to recurrence and shorter PSADT or higher PSA velocity are associated with adverse outcomes.
    • Limited evidence for Grade group, T stage, and short-term hormone therapy in post-radiotherapy BCR.

    Conclusions:

    • This review provides evidence for risk stratifying PCa recurrence.
    • Identified prognostic factors can personalize salvage treatment strategies.
    • Establishes a benchmark for guiding clinical decisions in recurrent prostate cancer.
    Docetaxel
    Enzalutamide
    Hormone therapy
    Prostatic neoplasms
    Systematic review
    Therapeutics